274 related articles for article (PubMed ID: 26914924)
1. Acute relapse after initiation of Siponimod in a patient with secondary progressive MS.
Hussain R; O'Leary S; Pacheco FM; Zacharias TE; Litvak P; Sguigna P; Marder E; Kia K; Kooner K; Stüve O
J Neurol; 2016 Mar; 263(3):606-10. PubMed ID: 26914924
[TBL] [Abstract][Full Text] [Related]
2. Effects of baseline age and disease duration on the efficacy and safety of siponimod in patients with active SPMS: Post hoc analyses from the EXPAND study.
Hua LH; Bar-Or A; Cohan SL; Lublin FD; Coyle PK; Cree BA; Meng X; Su W; Cox GM; Fox RJ
Mult Scler Relat Disord; 2023 Jul; 75():104766. PubMed ID: 37245350
[TBL] [Abstract][Full Text] [Related]
3. Siponimod in the treatment of multiple sclerosis.
Goodman AD; Anadani N; Gerwitz L
Expert Opin Investig Drugs; 2019 Dec; 28(12):1051-1057. PubMed ID: 31603362
[No Abstract] [Full Text] [Related]
4. Spotlight on siponimod and its potential in the treatment of secondary progressive multiple sclerosis: the evidence to date.
Gajofatto A
Drug Des Devel Ther; 2017; 11():3153-3157. PubMed ID: 29138536
[TBL] [Abstract][Full Text] [Related]
5. Siponimod to treat secondary progressive multiple sclerosis.
Gajofatto A; Turatti M
Drugs Today (Barc); 2020 Jan; 56(1):37-46. PubMed ID: 32055804
[TBL] [Abstract][Full Text] [Related]
6. [Siponimod: a new view at the therapy of secondary progressive multiple sclerosis].
Krasnov VS; Kolontareva YM
Zh Nevrol Psikhiatr Im S S Korsakova; 2021; 121(7):124-129. PubMed ID: 34460168
[TBL] [Abstract][Full Text] [Related]
7. Peripheral oedema as an adverse effect of treatment of secondary progressive multiple sclerosis with siponimod: A case series.
Chang EH; Hardy TA
J Neuroimmunol; 2024 Apr; 389():578330. PubMed ID: 38493554
[TBL] [Abstract][Full Text] [Related]
8. Siponimod for the treatment of secondary progressive multiple sclerosis.
Dumitrescu L; Constantinescu CS; Tanasescu R
Expert Opin Pharmacother; 2019 Feb; 20(2):143-150. PubMed ID: 30517042
[TBL] [Abstract][Full Text] [Related]
9. Does Siponimod Exert Direct Effects in the Central Nervous System?
Kipp M
Cells; 2020 Jul; 9(8):. PubMed ID: 32722245
[TBL] [Abstract][Full Text] [Related]
10. Siponimod Attenuates Neuronal Cell Death Triggered by Neuroinflammation via NFκB and Mitochondrial Pathways.
Gurrea-Rubio M; Wang Q; Mills EA; Wu Q; Pitt D; Tsou PS; Fox DA; Mao-Draayer Y
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38473703
[TBL] [Abstract][Full Text] [Related]
11. Indirect comparisons of siponimod with fingolimod and ofatumumab in multiple sclerosis: assessing the feasibility of propensity score matching analyses.
Samjoo IA; Worthington E; Haltner A; Spin P; Drudge C; Cameron C; Brennan R; Dahlke F; Adlard N
Curr Med Res Opin; 2021 Nov; 37(11):1933-1944. PubMed ID: 34384311
[TBL] [Abstract][Full Text] [Related]
12. [The efficacy and safety of siponimod in the Russian population of patients with secondary progressive multiple sclerosis].
Evdoshenko EP; Neofidov NA; Bakhtiyarova KZ; Davydovskaya MV; Kairbekova EI; Kolontareva YM; Malkova NA; Odinak MM; Popova EV; Sazonov DV; Stolyarov ID; Smagina IV; Fedyanin AS; Habirov FA; Khaibullin TI; Khachanova NV; Shchukin IA; Boyko AN
Zh Nevrol Psikhiatr Im S S Korsakova; 2019; 119(10. Vyp. 2):110-119. PubMed ID: 31934996
[TBL] [Abstract][Full Text] [Related]
13. The Two Sides of Siponimod: Evidence for Brain and Immune Mechanisms in Multiple Sclerosis.
Cohan SL; Benedict RHB; Cree BAC; DeLuca J; Hua LH; Chun J
CNS Drugs; 2022 Jul; 36(7):703-719. PubMed ID: 35725892
[TBL] [Abstract][Full Text] [Related]
14. Siponimod: First Global Approval.
Al-Salama ZT
Drugs; 2019 Jun; 79(9):1009-1015. PubMed ID: 31144287
[TBL] [Abstract][Full Text] [Related]
15. Siponimod (Mayzent)--a new drug for multiple sclerosis.
Med Lett Drugs Ther; 2019 May; 61(1571):70-72. PubMed ID: 31169805
[No Abstract] [Full Text] [Related]
16. Impact of Siponimod on Enteric and Central Nervous System Pathology in Late-Stage Experimental Autoimmune Encephalomyelitis.
Weier A; Enders M; Kirchner P; Ekici A; Bigaud M; Kapitza C; Wörl J; Kuerten S
Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430692
[TBL] [Abstract][Full Text] [Related]
17. [The first russian experience of use of siponimod in real clinical practice].
Prakhova LN; Ilves AG
Zh Nevrol Psikhiatr Im S S Korsakova; 2022; 122(7):138-141. PubMed ID: 35904305
[TBL] [Abstract][Full Text] [Related]
18. Siponimod: A Review in Secondary Progressive Multiple Sclerosis.
Scott LJ
CNS Drugs; 2020 Nov; 34(11):1191-1200. PubMed ID: 33108633
[TBL] [Abstract][Full Text] [Related]
19. Autonomic nervous system abnormalities predict cardiovascular changes after initiation of siponimod in secondary progressive multiple sclerosis.
Habek M; Crnošija L; Junaković A; Adamec I; Barun B; Gabelić T; Krbot Skorić M
Clin Neurophysiol; 2021 Feb; 132(2):581-585. PubMed ID: 33461086
[TBL] [Abstract][Full Text] [Related]
20. Long-term efficacy and safety of siponimod in patients with secondary progressive multiple sclerosis: Analysis of EXPAND core and extension data up to >5 years.
Cree BA; Arnold DL; Fox RJ; Gold R; Vermersch P; Benedict RH; Bar-Or A; Piani-Meier D; Rouyrre N; Ritter S; Kilaru A; Karlsson G; Giovannoni G; Kappos L
Mult Scler; 2022 Sep; 28(10):1591-1605. PubMed ID: 35380078
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
